中国药物经济学2025，Vol.20Issue(6)：5-9,5.DOI:10.12010/j.issn.1673-5846.2025.06.001
固本咳喘颗粒治疗慢性支气管炎的药物经济学评价
Pharmacoeconomic Evaluation of Guben Kechuan Granules for the Treatment of Chronic Bronchitis
摘要
Abstract
Objective To evaluate the economic viability of Guben Kechuan Granules in the treatment of chronic bronchitis.Methods Based on the randomized clinical trial report of Guben Kechuan Granules in the treatment of chronic bronchitis,it was determined that the enrolled patients were Chinese patients with chronic bronchitis.The full analysis set(FAS)experimental group had 119 cases of Guben Kechuan Granules,the positive drug group had 120 cases of Guilong Kechuanning Capsules,and the blank group had 60 cases of conventional treatment.The research perspective is the entire society,and the total cost includes direct costs and indirect costs.The main indicator of health output is the number of acute exacerbations of chronic bronchitis after one year of treatment,and the secondary indicator is quality-adjusted life years(QALYs).Based on the individual data of the research,cost-effectiveness and cost-utility analyses were conducted respectively,and univariate and probabilistic sensitivity analyses were carried out.Results The Guben Kechuan Granule group has a lower cost and better effect compared with the Guilong Kechuanning Capsule group,and it is an absolutely advantageous strategy with economy.Compared with the blank group,the Guben Kechuan Granule group had a higher cost but a better effect.The incremental cost-effectiveness ratio(ICER)was 795.17,meaning that an additional 795.17 yuan is required to prevent one acute exacerbation.Compared with the Guilong Kechuanning Capsule group,the Guben Kechuan Granule group saved 404.85 yuan in cost,and the incremental utility was 0.005 3 QALYs,which was an absolutely advantageous strategy with economy.Compared with the blank group,the incremental cost of the Guben Kechuan Granules group was 803.12 yuan,the incremental utility was 0.026 6 QALYs,the incremental cost-utility ratio(ICUR)was 30 192.48,which was less than one times the national per capita GDP of 89,358 yuan,and it was economical.The results of the sensitivity analysis were consistent with those of the basic analysis.Conclusion Compared with Guilong Kechuanning Capsules and conventional treatments,Guben Kechuan Granules are economically viable in the treatment of chronic bronchitis.关键词
固本咳喘颗粒/桂龙咳喘宁胶囊/慢性支气管炎/成本-效果/成本-效用Key words
Guben Kechuan Granules/GuiLong Kechuanning Capsules/Chronic bronchitis/Cost-effectiveness/Cost-utility分类
医药卫生引用本文复制引用
杨道文,张洪春..固本咳喘颗粒治疗慢性支气管炎的药物经济学评价[J].中国药物经济学,2025,20(6):5-9,5.基金项目
中医药传承与创新"百千万"人才工程(岐黄工程)岐黄学者项目(2019-QTL-003) （岐黄工程）
